| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| amlodipine besilate | Tablet, uncoated | 6.94 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| ropinirole hydrochloride | Tablet, film coated | .57 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| olanzapine | Tablet, orally disintegrating | 20 mg | Resolved | Available | Manufacturing | 24/01/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| donepezil hydrochloride | Tablet, film coated | 10 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 24/01/2025 |
| donepezil hydrochloride | Tablet, film coated | 5 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/01/2025 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 320 mg~25 mg | Anticipated | Available | Manufacturing | 24/01/2025 |
| hydrochlorothiazide~valsartan | Tablet, film coated | 12.5 mg~160 mg | Anticipated | Available | Manufacturing | 24/01/2025 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| afatinib dimaleate | Tablet, film coated | 73.9 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/01/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Current | Limited Availability | Unexpected increase in consumer demand | 24/01/2025 |
| simvastatin | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| amiodarone hydrochloride | Injection, solution | 150 mg | Anticipated | Available | 24/01/2025 | |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| tadalafil | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| solifenacin succinate | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| solifenacin succinate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| pregabalin | Capsule, hard | 25 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 24/01/2025 |
| naloxone hydrochloride dihydrate | Spray, nasal | 2.2 mg/actuation | Current | Limited Availability | Unexpected increase in consumer demand | 24/01/2025 |
| adrenaline (epinephrine) | Injection, solution | 500 microgram | Anticipated | Available | Manufacturing | 24/01/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 24/01/2025 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Resolved | Available | Manufacturing | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 24/01/2025 |
| levothyroxine sodium | Tablet, uncoated | .1 mg | Current | Unavailable | Commercial Changes / Commercial viability | 24/01/2025 |
| tobramycin | Injection, solution | 40 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 24/01/2025 |
| famotidine | Tablet, film coated | 20 mg | Current | Unavailable | Manufacturing | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 24/01/2025 |
| midazolam | Injection, solution | 5 mg/mL | Current | Limited Availability | Manufacturing | 23/01/2025 |
| topiramate | Tablet, film coated | 200 mg | Current | Limited Availability | Manufacturing | 23/01/2025 |
| venlafaxine hydrochloride | Capsule, modified release | 169.71 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 23/01/2025 |
| losartan potassium | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 23/01/2025 |
| losartan potassium | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 23/01/2025 |
| insulin | Injection, solution | 100 IU/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 23/01/2025 |
| levetiracetam | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 23/01/2025 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Resolved | Available | Manufacturing | 23/01/2025 |
| tobramycin | Injection, solution | 40 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 23/01/2025 |
| voriconazole | Injection, powder for | 200 mg | Resolved | Available | Manufacturing | 23/01/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 23/01/2025 |
| celecoxib | Capsule, hard | 100 mg | Current | Limited Availability | Manufacturing | 23/01/2025 |
| emtricitabine~tenofovir disoproxil succinate | Tablet, film coated | 200 mg~300.6 mg | Current | Unavailable | Manufacturing | 23/01/2025 |
| chloramphenicol | Eye Drops, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 23/01/2025 |
| gemfibrozil | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 23/01/2025 |
| doxycycline hyclate | Tablet, film coated | 57.5 mg | Current | Limited Availability | Manufacturing | 23/01/2025 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 23/01/2025 |
| sugammadex sodium | Injection, solution | 544 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 22/01/2025 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 22/01/2025 |
| phenoxymethylpenicillin potassium | Tablet, film coated | 280 mg | Current | Limited Availability | Manufacturing | 22/01/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, multilayer | 10 mg~21.7 mg | Current | Limited Availability | Manufacturing | 22/01/2025 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Limited Availability | Manufacturing | 22/01/2025 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Current | Unavailable | Manufacturing | 22/01/2025 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/01/2025 |
| levothyroxine sodium | Tablet, uncoated | .075 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/01/2025 |
| levothyroxine sodium | Tablet, uncoated | .025 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/01/2025 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/01/2025 |
| levothyroxine sodium | Tablet, uncoated | .2 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/01/2025 |
| isosorbide dinitrate | Tablet, uncoated | 5 mg | Resolved | Available | Manufacturing | 21/01/2025 |
| hydrocortisone acetate | Eye Ointment | 10 mg/g | Current | Limited Availability | Manufacturing | 21/01/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 21/01/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Anticipated | Available | Manufacturing | 21/01/2025 |
| bisoprolol fumarate | Tablet | 10 mg | Current | Limited Availability | Manufacturing | 21/01/2025 |
| eftrenonacog alfa | Injection, powder for | 250 IU | Current | Unavailable | Unexpected increase in consumer demand | 21/01/2025 |
| desvenlafaxine | Tablet, modified release | 50 mg | Resolved | Available | Manufacturing | 21/01/2025 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Resolved | Available | Manufacturing | 21/01/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 21/01/2025 |
| anastrozole | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 21/01/2025 |
| irbesartan~hydrochlorothiazide | Tablet, film coated | 300 mg~12.5 mg | Current | Limited Availability | Manufacturing | 21/01/2025 |
| bupivacaine hydrochloride monohydrate~adrenaline (epinephrine) acid tartrate | Injection, solution | 5.27 mg/mL~9.1 microgram/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 21/01/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 41.363 mg~10 mg | Current | Unavailable | Manufacturing | 21/01/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~20.681 mg | Current | Unavailable | Manufacturing | 21/01/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~82.725 mg | Current | Unavailable | Manufacturing | 21/01/2025 |
| dutasteride~tamsulosin hydrochloride | Capsule, modified release | 500 microgram~400 microgram | Current | Unavailable | Manufacturing | 21/01/2025 |
| carboplatin | Injection, solution | 10 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 21/01/2025 |
| azithromycin dihydrate | Suspension, powder for | 209.65 mg | Resolved | Available | Unexpected increase in consumer demand | 21/01/2025 |
| ketamine hydrochloride | Injection, solution | 115.3 mg/mL | Current | Limited Availability | Manufacturing | 21/01/2025 |
| pioglitazone hydrochloride | Tablet, uncoated | 33.06 mg | Anticipated | Available | Manufacturing | 21/01/2025 |
| olanzapine | Injection, powder for | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 21/01/2025 |
| testosterone enantate | Injection | 250 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 20/01/2025 |
| topiramate | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 20/01/2025 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 20/01/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Limited Availability | Manufacturing | 20/01/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Anticipated | Available | Unexpected increase in consumer demand | 20/01/2025 |
| praziquantel | Tablet, film coated | 600 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 20/01/2025 |
| ivabradine hydrochloride | Tablet, film coated | 5.39 mg | Current | Limited Availability | Manufacturing | 20/01/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Current | Limited Availability | Manufacturing | 20/01/2025 |
| rosuvastatin calcium | Tablet, film coated | 20.84 mg | Resolved | Available | Manufacturing | 20/01/2025 |
| cabergoline | Tablet, uncoated | 1 mg | Current | Unavailable | Manufacturing | 20/01/2025 |
2025年1月27日